5-MBPB

5-MBPB
Clinical data
ATC code	none;
Legal status
Legal status	CA: Schedule I; DE: NpSG (Industrial and scientific use only); UK: Class B;
Identifiers
	IUPAC name 1-(1-benzofuran-5-yl)-N-methylbutan-2-amine;
PubChem CID	139033209;
ChemSpider	52085237;
UNII	YHB7YWS4WJ;
CompTox Dashboard (EPA)	DTXSID601336210 ;
Chemical and physical data
Formula	C13H17NO
Molar mass	203.28 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC(CC1=CC2=C(OC=C2)C=C1)NC;
	InChI InChI=1S/C13H17NO/c1-3-12(14-2)9-10-4-5-13-11(8-10)6-7-15-13/h4-8,12,14H,3,9H2,1-2H3; Key:CTEZPBCLIKEASW-UHFFFAOYSA-N;

5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine and phenylisobutylamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.^[1]

Quick facts Clinical data, ATC code ...

5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT_2C receptor.^[2]

5-MBPB (5-MABB) has been found to act as a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA), with preference for induction of serotonin release over norepinephrine and dopamine release, and fully substitutes for MDMA in animal drug discrimination tests.^[3] Unlike 5-MAPB, it is a relatively weak serotonin 5-HT_1B receptor agonist.^[4]

See also